Mayne Pharma Group Ltd. of Australia has agreed to buy a portfolio of US generic products from Teva Pharmaceutical Industries Ltd. and Allergan PLC for $652m. The portfolio consists of 37 approved products and 5 FDA-filed products in a range of territories and indications.
The two larger companies are making a series of divestments to gain antitrust approval for Teva's acquisition of Allergan's generics...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
